





Application of a high throughput, multi-parametric single-cell assay to assess the diversity in drug effects on multiple cell populations



-  **322**
- Healthy donors
 - Patients with hematological malignancies: acute myeloid leukemia (AML), multiple myeloma (MM), others



 High throughput flow cytometry



 Drug exposure

-  **Venetoclax** ▶
- similar cell specific effects in all tested samples independently whether healthy or malignant
 - the variation in response is purely lineage specific
-  **Midostaurin** ▶
- effect on CD19⁺/B cells (median IC₅₀, 314 nM) was comparable to FLT3-ITD mutated AML CD34⁺CD38⁺ blasts

Comparison of drug responses in healthy and neoplastic cells showed that healthy cell responses are predictive of the corresponding malignant cell response